Sarepta cements its DMD throne with $1B+ gene therapy deal with mighty Roche
Pop the champagne, Sarepta has done it again.
Days before Christmas, the keenly watched drugmaker has clinched a deal with Roche. The large Swiss drugmaker is parting with a staggering $1.15 billion — $750 million in upfront cash and $400 million in equity — for the rights to Sarepta’s experimental gene therapy for Duchenne muscular dystrophy outside the United States.
Sarepta — which will retain the US rights to the drug, SRP-9001 — is eligible to receive another $1.7 billion in regulatory and sales milestones, in addition to royalties. Roche will also shoulder half the development costs for the therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.